Nilotinib in first-line treatment of chronic myeloid leukemia
10.3760/cma.j.issn.1673-422X.2020.01.011
- VernacularTitle:尼洛替尼一线治疗慢性髓系白血病的进展
- Author:
Li HONG
1
;
Yu WANG
;
Qi ZHANG
;
Chengfang LYU
Author Information
1. 哈尔滨医科大学附属第一医院血液内科 150001
- From:
Journal of International Oncology
2020;47(1):56-59
- CountryChina
- Language:Chinese
-
Abstract:
Chronic myeloid leukemia (CML) is a myeloproliferative tumor whose pathogenesis is related to the BCR/ABL fusion gene. Tyrosine kinase inhibitors (TKIs) can significantly improve the survival and prognosis of CML patients. Nilotinib is effective in first-line treatment of CML patients with rapid response, deep remission and high safety. After achieving a sustained deep molecular response, it is a new therapeutic goal for CML to stop the use of nilotinib and achieve treatment-free remission. In addition, due to disease resistance and mutations, how to start new treatments after nilotinib treatment failure is worth further research.
